AstraZeneca Pharma India reports that its net profit for the quarter ended June 2026 declines to about ₹38 crore, down year-on-year. Business Line puts the figure at ₹37.93 crore, while NDTV reports a similar amount at roughly ₹38 crore, describing it as a 32% fall.
Both outlets say revenue from operations rises sharply in the same quarter. NDTV reports revenue growth of about 30% year-on-year to around ₹682.8 crore, compared with ₹526.3 crore a year earlier. Business Line also cites revenue from operations at ₹682.79 crore versus ₹526.31 crore in the prior year period. The articles focus on the contrast between higher sales and lower profit, without detailing reasons for the profit decline.
Overall, the coverage aligns on the direction and magnitude of both net profit and revenue changes, differing mainly in how the profit drop is expressed (₹37.93 crore vs “about ₹38 crore” and percentage framing).
